Evidence map›Paper›PMID 38197913›Full record

ArticleArchives of toxicology2024

Development of an adverse outcome pathway network for nephrotoxicity.

D A Barnes, J W Firman, S J Belfield, M T D Cronin, M Vinken, M J Janssen, R Masereeuw

Open access · hybridAbstract read
In one paragraph

Article in Archives of toxicology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
5.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Unveiling toxicological adverse outcomes: toward construction and simulation of large-scale networks.Toxicological sciences : an official journal of the Society of Toxicology · 2026
    Review
  3. Review
  4. Article
  5. Article
  6. An AOP-guidedNAM journal · 2026
    Article
  7. Article
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 3 countries.

D A BarnesDivision of Pharmacology, Utrecht University, Utrecht Institute for Pharmaceutical Sciences, Utrecht, The Netherlands.ORCID 0000-0003-2037-2824
J W FirmanSchool of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Liverpool, UK.ORCID 0000-0003-0319-1407
S J BelfieldSchool of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Liverpool, UK.ORCID 0000-0002-6532-2532
M T D CroninSchool of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Liverpool, UK.ORCID 0000-0002-6207-4158
M VinkenDepartment of Pharmaceutical and Pharmacological Sciences, Entity of In Vitro Toxicology and Dermato-Cosmetology, Vrije Universiteit Brussel, Brussels, Belgium.ORCID 0000-0001-5115-8893
M J JanssenDivision of Pharmacology, Utrecht University, Utrecht Institute for Pharmaceutical Sciences, Utrecht, The Netherlands.ORCID 0000-0002-0544-8096
R MasereeuwDivision of Pharmacology, Utrecht University, Utrecht Institute for Pharmaceutical Sciences, Utrecht, The Netherlands. r.masereeuw@uu.nl.ORCID 0000-0002-1560-1074
Liverpool John Moores University · GBUtrecht University · NLVrije Universiteit Brussel · BE

Funding

Horizon 2020 Framework Programme No. 963845Horizon 2020 Framework Programme No. 964537
6 · The paper itself

Abstract

Adverse outcome pathways (AOPs) were introduced in modern toxicology to provide evidence-based representations of the events and processes involved in the progression of toxicological effects across varying levels of the biological organisation to better facilitate the safety assessment of chemicals. AOPs offer an opportunity to address knowledge gaps and help to identify novel therapeutic targets. They also aid in the selection and development of existing and new in vitro and in silico test methods for hazard identification and risk assessment of chemical compounds. However, many toxicological processes are too intricate to be captured in a single, linear AOP. As a result, AOP networks have been developed to aid in the comprehension and placement of associated events underlying the emergence of related forms of toxicity-where complex exposure scenarios and interactions may influence the ultimate adverse outcome. This study utilised established criteria to develop an AOP network that connects thirteen individual AOPs associated with nephrotoxicity (as sourced from the AOP-Wiki) to identify several key events (KEs) linked to various adverse outcomes, including kidney failure and chronic kidney disease. Analysis of the modelled AOP network and its topological features determined mitochondrial dysfunction, oxidative stress, and tubular necrosis to be the most connected and central KEs. These KEs can provide a logical foundation for guiding the selection and creation of in vitro assays and in silico tools to substitute for animal-based in vivo experiments in the prediction and assessment of chemical-induced nephrotoxicity in human health.

Indexed as

Adverse Outcome PathwaysAnimal ExperimentationDrug-Related Side Effects and Adverse ReactionsRenal InsufficiencyAnimalsHumansRisk AssessmentAdverse outcome pathwayKey eventsMolecular initiating eventNephrotoxicityNew approach methodology

Identifiers

PMID38197913
PMCPMC10861692
OpenAlexW4390694785

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.